Science Explorer Back to mapMap
Discussion
Topic · Pulmonary and Respiratory Medicine

Renal cell carcinoma treatment

Renal cell carcinoma treatment is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 36k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers represents a comprehensive exploration of advancements in the research and treatment of renal cell carcinoma, including studies on various treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines.

  • Renal Cell Carcinoma
  • Metastatic
  • Treatment
  • Therapy
  • Prognostic Factors
  • Molecular Characterization
  • Nephron-Sparing Surgery
  • Immunotherapy
  • Genetic Mutations
  • Clinical Guidelines
Research works
36k
fractional, since 1950
In the world top 10%
3.7k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+7%
the tick is no change
Largest producer
United States
31% of the 10 largest, 2022-now
Renal cell carcinoma treatment

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Renal cell carcinoma treatment research?

By volume, the United States and China publish the most (1.9k and 1.8k works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.9k works
  2. 2 China 1.8k works
  3. 3 Japan 585 works
  4. 4 Italy 430 works
  5. 5 India 345 works
  6. 6 Germany 316 works
  7. 7 United Kingdom 278 works
  8. 8 France 256 works
  9. 9 South Korea 179 works
  10. 10 Türkiye 174 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 30.7%China: 28.6%Japan: 9.3%Italy: 6.8%6 others listed: 24.6%31%largest
United States1,936 · 30.7%China1,799 · 28.6%Japan585 · 9.3%Italy430 · 6.8%6 others listed1,549 · 24.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Renal cell carcinoma treatment research?

By volume in 2022-now, Harvard University publishes the most Renal cell carcinoma treatment research, followed by Shanghai Jiao Tong University and Peking University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 117 works
  2. 2 Shanghai Jiao Tong UniversityChina 69 works
  3. 3 Peking UniversityChina 67 works
  4. 4 Sun Yat-sen UniversityChina 67 works
  5. 5 Sichuan UniversityChina 66 works
  6. 6 The University of Texas MD Anderson Cancer CenterUnited States 65 works
  7. 7 Mayo ClinicUnited States 57 works
  8. 8 Memorial Sloan Kettering Cancer CenterUnited States 48 works
  9. 9 Nanjing Medical UniversityChina 41 works
  10. 10 The University of Texas Southwestern Medical CenterUnited States 39 works

Who are the leading researchers in Renal cell carcinoma treatment?

The most-cited researchers publishing on Renal cell carcinoma treatment include Ahmedin Jemal, Freddie Bray and George Davey Smith.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Freddie Bray France 550k citations
  3. 3 George Davey Smith United Kingdom 435k citations
  4. 4 Ali H. Mokdad United States 429k citations
  5. 5 Walter Churchill Willett United States 411k citations
  6. 6 Stacey L. Gabriel United States 402k citations
  7. 7 Robert John Tibshirani United States 396k citations
  8. 8 Bert Vogelstein United States 373k citations
  9. 9 Gad A. Getz United States 364k citations
  10. 10 Elaine R. Mardis United States 346k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Renal cell carcinoma treatment?

The most cited paper in Renal cell carcinoma treatment is "Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review" (Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al., 2017), with 15,286 citations. Next come "Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing" (7,931) and "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma" (5,972).

Most cited papers
#PaperReleasedCitations
1 Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al. · American Journal of Nephrology ReviewOpen access 2017 15,286
2 Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Marco Gerlinger et al. · New England Journal of Medicine Open access 7 Mar 2012 7,931
3 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access 25 Sep 2015 5,972
4 Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine Open access 10 Jan 2007 5,801
5 Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine Open access 10 Jan 2007 4,813
All 98 most cited papers, with filters and sorting

Where is Renal cell carcinoma treatment research done?

The largest centres of Renal cell carcinoma treatment research in 2022-now are Beijing (China), Shanghai (China), Tokyo (Japan) and New York (United States).

Largest cities, 2022-now

  1. 1 BeijingChina 232 works
  2. 2 ShanghaiChina 177 works
  3. 3 TokyoJapan 147 works
  4. 4 New YorkUnited States 118 works
  5. 5 GuangzhouChina 117 works
  6. 6 SeoulSouth Korea 104 works
  7. 7 BostonUnited States 104 works
  8. 8 LondonUnited Kingdom 92 works
  9. 9 MoscowRussia 86 works
  10. 10 HoustonUnited States 86 works
See Renal cell carcinoma treatment on the map

Where is the best place to study Renal cell carcinoma treatment?

Among universities, judged by research, Harvard University, University of Bari Aldo Moro and Sichuan University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 17.38%fractional works in this field (log) →share of work in the world top 10% →University of Bari A…Harvard UniversitySichuan UniversitySun Yat-sen University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 74.518.5%5.2×118 -4.5%
2University of Bari Aldo MoroItaly 65.433.8%5.1×12 +105.7%
3Sichuan UniversityChina 56.213.1%4.2×66 +96.0%
4Sun Yat-sen UniversityChina 56.011.7%4.6×67 +43.5%
5University of TorontoCanada 55.316.6%2.2×32 -1.9%
6Shanghai Jiao Tong UniversityChina 54.912.0%3.4×68 +76.1%
7Johns Hopkins UniversityUnited States 54.615.5%3.5×38 -3.2%
8University of FlorenceItaly 54.219.1%5.3×23 +16.9%
9Cornell UniversityUnited States 54.015.4%3.0×28 +13.7%
10Medical University of ViennaAustria 51.118.1%5.8×13 +26.1%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Renal cell carcinoma treatment, country by country

Is Renal cell carcinoma treatment research growing?

Output in 2022-2025 was 7% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Renal cell carcinoma treatment.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Renal cell carcinoma treatment as a percentage of every work published that year, 0.032% in 2024.

still counting0.020%0.040%0.060%Renal cell carcinoma treatment0.033% in 202519801990200020102020

Fractional works of Renal cell carcinoma treatment over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Renal cell carcinoma treatment10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Renal cell carcinoma treatment. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.